Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 282

Showing 1-25 of 282 citing articles:

The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Cuprous oxide nanocomposites with photothermal (PTT) and chemical dynamics (CDT) effects induce cuproptosis in breast cancer using the strategy of increasing inflow and reducing outflow
Wei Li, Yao Xiao, Guohu Guo, et al.
Nano Today (2024) Vol. 56, pp. 102223-102223
Open Access | Times Cited: 25
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei Wei, Zhi‐Nan Chen, Ke Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12317-12317
Open Access | Times Cited: 40
Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
Abdelrahman Abaza, Faten Sid Idris, Humna Anis Shaikh, et al.
Cureus (2023)
Open Access | Times Cited: 34
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors
Joseph Toker, J. Bryan Iorgulescu, Alexander Ling, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 12, pp. 2226-2238
Open Access | Times Cited: 25
A polysaccharide from Inula japonica showing in vivo antitumor activity by interacting with TLR-4, PD-1, and VEGF
Xuelian Wang, Yeling Li, Wenhui Liu, et al.
International Journal of Biological Macromolecules (2023) Vol. 246, pp. 125555-125555
Closed Access | Times Cited: 24
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 24
The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles
Yixiang Hu, Ya Liu, Lijuan Zong, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 12
Open Access | Times Cited: 23
A new strategy for immunotherapy of microsatellite‐stable (MSS)‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD‐1/PD‐L1 inhibitors
Lingli Cai, Anqi Chen, Dong Tang
Immunology (2024) Vol. 173, Iss. 2, pp. 209-226
Open Access | Times Cited: 14
Structure and antitumor activity of a polysaccharide from Rosa roxburghii
Wenhui Liu, Na Li, Jiantong Hou, et al.
International Journal of Biological Macromolecules (2024) Vol. 273, pp. 132807-132807
Closed Access | Times Cited: 13
Immunology of bile acids regulated receptors
Stefano Fiorucci, Silvia Marchianò, Ginevra Urbani, et al.
Progress in Lipid Research (2024) Vol. 95, pp. 101291-101291
Closed Access | Times Cited: 13
Gastric Cancer - Epidemiology, Modifiable and Non-modifiable Risk Factors, Challenges and Opportunities: An Updated Review
Tajul Islam Mamun, Sabrina Younus, Md Hashibur Rahman
Cancer Treatment and Research Communications (2024) Vol. 41, pp. 100845-100845
Open Access | Times Cited: 12
Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
Jin Zhang, Yue Ma
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116909-116909
Open Access | Times Cited: 11
Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products
Lele Zhang, Jin‐Jian Lu
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 1, pp. 1-3
Closed Access | Times Cited: 10
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 10
Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Maciej Jaromin, Tomasz Konecki, Piotr Kutwin
Cancers (2024) Vol. 16, Iss. 7, pp. 1366-1366
Open Access | Times Cited: 9
An antitumor arabinan from Glehnia littoralis activates immunity and inhibits angiogenesis
Wenhui Liu, Kexin Li, Han Zhang, et al.
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130242-130242
Closed Access | Times Cited: 8
A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification
Jiachen Xu, Yundi Zhang, Man Li, et al.
EBioMedicine (2024) Vol. 102, pp. 105092-105092
Open Access | Times Cited: 8
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 8
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications
Xiaohang Feng, Z Y Li, Yuping Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature
Orazio De Tommasi, Matteo Marchetti, Marta Tripepi, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 401-401
Open Access | Times Cited: 1
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis
Huan Han, Hanwen Su, Zhihua Lv, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 185-185
Open Access | Times Cited: 1
Genetic Risk Profiling Reveals Altered Glycosyltransferase Expression as a Predictor for Patient Outcome in Neuroblastoma
Isabelle Ariane Bley, S. Behrens, Michael Spohn, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 527-527
Open Access | Times Cited: 1
Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy
Moon Nyeo Park, Jinwon Choi, Md. Maharub Hossain Fahim, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top